INTRODUCTION

Our objective was to compare [Cu]Cu-NOTA-panitumumab F(ab') and [Lu]Lu-NOTA-panitumumab F(ab') radioimmunotherapy (RIT) agents for decreasing the clonogenic survival fraction (SF) in vitro of EGFR-positive human pancreatic ductal adenocarcinoma (PDAC) cell lines and estimate the relative biological effectiveness (RBE) vs. γ-radiation (XRT).

METHODS

EGFR-positive PDAC cell lines (AsPC-1, PANC-1, MIAPaCa-2, Capan-1) and EGFR-knockout PANC-1 EGFR KO cells were treated in vitro for 18 h with (0-19.65 MBq; 72 nmols/L) of [Cu]Cu-NOTA-panitumumab F(ab') or [Lu]Lu-NOTA-panitumumab F(ab') or XRT (0-8 Gy) followed by clonogenic assay. The SF was determined after culturing single treated cells for 14 d. Cell fractionation studies were performed for cells incubated with 1 MBq (72 nmols/L) of [Cu]Cu-NOTA-panitumumab F(ab') or [Lu]Lu-NOTA-panitumumab F(ab') for 1, 4, or 24 h to estimate the time-integrated activity (Ã) on the cell surface, cytoplasm, nucleus and medium. Radiation absorbed doses in the nucleus were calculated by multiplying à by S-factors calculated by Monte Carlo N Particle (MCNP) modeling using monolayer cell culture geometry. The SF of PDAC cells was plotted vs. dose and fitted to a linear quadratic model to estimate the dose required to decrease the SF to 0.1 (D). The D for RIT agents were compared to XRT to estimate the RBE. DNA double-strand breaks (DSBs) caused by [Cu]Cu-NOTA-panitumumab F(ab') or [Lu]Lu-NOTA-panitumumab F(ab') continuous exposure for 5 h or 20 h were probed by immunofluorescence for γ-H2AX. Relative EGFR expression of PDAC cells was assessed by flow cytometry (scored + to +++) and cell doubling times for untreated cells were determined.

RESULTS

The D for [Cu]Cu-NOTA-panitumumab F(ab') ranged from 9.1 Gy (PANC-1) to 39.9 Gy (Capan-1). The D for [Lu]Lu-NOTA-panitumumab F(ab') ranged from 11.7 Gy (AsPC-1) to 170.8 Gy (Capan-1). The D for XRT ranged from 2.5 Gy (Capan-1) to 6.7 Gy (PANC-1 EGFR KO). D values were not correlated with EGFR expression over a relatively narrow range (++ to +++) or with cell doubling times. Based on D values, PANC-1 EGFR KO cells were 1.6-fold less sensitive than PANC-1 cells to [Cu]Cu-NOTA-panitumumab F(ab') and 1.9-fold less sensitive to [Lu]Lu-NOTA-panitumumab F(ab'). The RBE for [Cu]Cu-NOTA-panitumumab F(ab') ranged from 0.06 for Capan-1 cells to 0.45 for PANC-1 cells. The RBE for [Lu]Lu-NOTA-panitumumab F(ab') ranged from 0.015 for Capan-1 cells to 0.28 for AsPC-1 cells. DNA DSBs were detected in PDAC cells exposed to [Cu]Cu-NOTA-panitumumab F(ab') or [Lu]Lu-NOTA-panitumumab F(ab') but were not correlated with the SF of the cells.

CONCLUSIONS

We conclude that at the same dose delivered to the cell nucleus [Cu]Cu-NOTA-panitumumab F(ab') and [Lu]Lu-NOTA-panitumumab F(ab') were less radiobiologically effective than XRT for decreasing the SF of human PDAC cells, but [Cu]Cu-NOTA-panitumumab F(ab') was more cytotoxic than [Lu]Lu-NOTA-panitumumab F(ab') except for AsPC-1 cells which were more sensitive to [Lu]Lu-NOTA-panitumumab F(ab').

ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE

This study demonstrates that higher radiation doses may be required for RIT than XRT to achieve radiobiologically equivalent effects when used to treat PDAC.